Lexeo Therapeutics (LXEO) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Protalix BioTherapeutics (DE) (PLX) has outperformed Lexeo Therapeutics (LXEO) over the past year, gaining 65.7% versus a loss of 67.3%. Lexeo Therapeutics is the larger company by market cap ($245.1 million vs $244.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LXEO | PLX |
|---|---|---|
| Share price | $2.96 | $2.90 |
| Market cap | $245.05M | $244.52M |
| 1-day change | +0.34% | -5.23% |
| YTD return | -70.19% | +61.11% |
| 1-year return | -67.33% | +65.71% |
| 5-year return | — | +192.93% |
| P/E ratio (TTM) | — | 12.08 |
| Forward P/E | — | 4.68 |
| EPS (TTM) | $-1.13 | $0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $52.74M |
| Revenue growth (YoY) | — | -1.23% |
| Net income (latest FY) | $-100.00M | $-6.60M |
| Gross margin | — | 48.82% |
| Operating margin | — | -10.43% |
| Net margin | — | -12.52% |
| 52-week high | $10.99 | $3.19 |
| 52-week low | $2.55 | $1.65 |
| Distance from 52-week high | -73.07% | -9.09% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +748.31% | +313.79% |
| Average volume | 1.98M | 903.48K |
| Shares outstanding | 82.79M | 84.32M |
| Employees | 68 | 226 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLX has outperformed LXEO by 133.0 percentage points over the past year.
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
LXEO vs PLX FAQ
Which is bigger, Lexeo Therapeutics or Protalix BioTherapeutics (DE)?
Lexeo Therapeutics (LXEO) is larger, with a market capitalization of $245.05M compared with $244.52M for Protalix BioTherapeutics (DE) (PLX).
Which stock has performed better over the past year, LXEO or PLX?
PLX returned +65.71% over the past 12 months, compared with -67.33% for LXEO (price return, excluding dividends). Past performance does not predict future results.
Are Lexeo Therapeutics and Protalix BioTherapeutics (DE) in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.